Valuation dashboard for Celularity Inc. (CELU) with P/E N/A, P/B -0.73, EV/EBITDA -0.91 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking.
Analysis Summary
Celularity Inc. reported revenue of $26.6M in the most recent fiscal year, growing at a 5-year CAGR of 13.2%.
Trailing-twelve-month margins: gross margin 76.0%, operating margin -230.9%, net margin -345.4%.
At the current price of $1.29, CELU has negative trailing earnings (P/E not meaningful) and an ROE of 411.46%. Market capitalisation stands at $37M.
Balance sheet quality for CELU: current ratio of 0.2. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -0.73 |
| EV / EBITDA | -0.91 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-15.24 |
| vs Current Price | -1281.1% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CELU | Celularity Inc. | $37M | 411.5% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.29 |
| Market Cap | $37M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 411.46% |
| Return on Invested Capital | -151.11% |
| Return on Assets | -85.45% |
| Gross Margin | 76.04% |
| Operating Margin | -230.92% |
| Net Margin | -345.44% |
Related companies: ANVS · ATNM · BCAB · BTAI · FGEN · GBIO · KZR
Explore sector: Healthcare · Biotechnology
More sections of CELU: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks